KEGG DRUG

Search results

No.	薬物名（臨床試験情報から抽出）	DrugBank	KEGG DRUG	KEGG GENES	KEGG PATHWAY	指定難病告示番号
1	Visilizumab (D06314)	1件: Visilizumab	1件: Visilizumab (D06314) 💬	3件: CD3D, CD3E, CD3G 💬	11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	2件: 96, 97 💬
2	Visilizumab (HuM291 (D06314)	1件: Visilizumab	1件: Visilizumab (D06314) 💬	3件: CD3D, CD3E, CD3G 💬	11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	1件: 97 💬
3	Visilizumab (Nuvion) (D06314)	1件: Visilizumab	1件: Visilizumab (D06314) 💬	3件: CD3D, CD3E, CD3G 💬	11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	1件: 97 💬
4	Visilizumab (Nuvion® (D06314)	1件: Visilizumab	1件: Visilizumab (D06314) 💬	3件: CD3D, CD3E, CD3G 💬	11件: Chagas disease, Epstein-Barr virus infection, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human immunodeficiency virus 1 infection, Measles, PD-L1 expression and PD-1 checkpoint pathway in cancer, Primary immunodeficiency, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation 💬	1件: 97 💬